A multicenter, randomized, parallel-group, double-blind, placebo-controlled flexible-dose study to assess the efficacy and safety of viagra (sildenafil citrate) in men with erectile dysfunction (ED) who do not self identify

Trial Profile

A multicenter, randomized, parallel-group, double-blind, placebo-controlled flexible-dose study to assess the efficacy and safety of viagra (sildenafil citrate) in men with erectile dysfunction (ED) who do not self identify

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2010

At a glance

  • Drugs Sildenafil (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Jun 2010 After 8 weeks, International Index of Erectile Function scores (primary endpoint) were better in recipients of sildenafil versus placebo (5.4 vs 1.1; p<0.001).
    • 23 Jun 2010 Results were published in Urology.
    • 07 Aug 2008 Patient numbers changed from 300 to 371 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top